SELLAS Life Sciences Group, Inc.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.0M | $7.6M | $1.9M | $0 | $9.3M | $2.5M | $0 |
| Cost of Revenue | $0 | $100.0K | $200.0K | $0 | — | $1.4M | $520.0K | $0 |
| Gross Profit | $0 | $900.0K | $7.4M | $1.9M | — | $7.9M | $2.0M | $0 |
| Gross Margin | — | 90.0% | 97.4% | 100.0% | — | 84.9% | 79.1% | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | $15.7M | $9.3M | $7.3M | — | — | $14.6M |
| SG&A Expense | $13.9M | $12.6M | $11.3M | $9.6M | $9.9M | — | — | $6.6M |
| Operating Income | $-37.9M | $-42.0M | $-25.3M | $-17.0M | $-20.0M | $-43.9M | $-28.5M | $-21.2M |
| Operating Margin | — | -4,195.0% | -332.8% | -893.8% | — | -471.1% | -1,145.5% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-37.3M | $-41.3M | $-20.9M | $-16.8M | $-19.4M | $-28.3M | $-70.3M | $-34.4M |
| Income Tax Expense | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $0 | $1.1M | $-1.1M |
| Net Income | $-37.3M | $-41.3M | $-20.7M | $-16.8M | $-19.3M | $-36.6M | $-76.7M | $-35.0M |
| Net Margin | — | -4,130.1% | -272.4% | -881.9% | — | -392.8% | -3,083.2% | — |
| EPS (Basic) | $-0.67 | $-1.07 | $-0.67 | $-1.06 | $-5.46 | $-3.07 | $-0.43 | $-0.28 |
| EPS (Diluted) | $-0.67 | $-1.07 | $-0.67 | $-1.06 | $-5.46 | $-3.07 | $-0.43 | $-0.28 |
| Shares Outstanding (Basic) | 55.6M | 38.8M | 31.0M | 16.0M | 10.2M | 218.9M | 218.9M | 165.8M |
| Shares Outstanding (Diluted) | 55.6M | 38.8M | 31.0M | 16.0M | 10.2M | 218.9M | 218.9M | 165.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |